Switch theme
Sign up to access all valuation multiples
CapsoVision Inc is a commercial-stage medical technology enterprise, innovates, manufactures, and markets endoscopic video imaging devices focused on internal imaging of the gastrointestinal (GI) system. Internal GI imaging facilitates earlier detection of colorectal cancer and other diseases, enabling more timely and effective treatment regimens for patients. The Company’s core technology platform is an orally ingestable capsule including multiple cameras facilitating 360-degree imaging, light-emitting diodes for measurement, onboard memory storage, and battery life permitting recording and onboard storage of video images. The Company’s products consist of the on-market CapsoCam Plus, directed at the small intestines, and the in-development CapsoColon 3D directed at the large intestines.
2005
90
Last FY Revenue $11.8M
Last FY EBITDA -$19.4M
$185M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, CapsoVision achieved revenue of $11.8M and an EBITDA of -$19.4M.
CapsoVision expects next 12-month revenue of XXX and NTM EBITDA of XXX
See CapsoVision valuation multiples based on analyst estimates| NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue | XXX | $11.8M | XXX | XXX | XXX |
| Gross Profit | XXX | $6.4M | XXX | XXX | XXX |
| Gross Margin | XXX | 54% | XXX | XXX | XXX |
| EBITDA | XXX | -$19.4M | XXX | XXX | XXX |
| EBITDA Margin | XXX | -165% | XXX | XXX | XXX |
| EBIT | XXX | -$19.9M | XXX | XXX | XXX |
| EBIT Margin | XXX | -169% | XXX | XXX | XXX |
| Net Profit | XXX | -$19.9M | XXX | XXX | XXX |
| Net Margin | XXX | -169% | XXX | XXX | XXX |
| Net Debt | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of August 13, 2025, CapsoVision's stock price is $4.
CapsoVision has current market cap of $189M, and EV of $185M.
See CapsoVision trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $185M | $189M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of August 13, 2025, CapsoVision has market cap of $189M and EV of $185M.
CapsoVision's trades at 15.8x EV/Revenue multiple, and -9.6x EV/EBITDA.
Equity research analysts estimate CapsoVision's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
CapsoVision's P/E ratio is not available.
See valuation multiples for CapsoVision and 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $189M | XXX | $189M | XXX | XXX | XXX |
| EV (current) | $185M | XXX | $185M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | 15.8x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -9.6x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | -9.3x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | -9.5x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -9.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialCapsoVision's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.3M for the same period.
CapsoVision's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
CapsoVision's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for CapsoVision and other 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -165% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 59% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 129% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 224% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
CapsoVision acquired XXX companies to date.
Last acquisition by CapsoVision was XXXXXXXX, XXXXX XXXXX XXXXXX . CapsoVision acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 65K+ M&A deals.
Start Free Trial| When was CapsoVision founded? | CapsoVision was founded in 2005. |
| Where is CapsoVision headquartered? | CapsoVision is headquartered in United States of America. |
| How many employees does CapsoVision have? | As of today, CapsoVision has 90 employees. |
| Who is the CEO of CapsoVision? | CapsoVision's CEO is Mr. Kang-Huai Johnny Wang. |
| Is CapsoVision publicy listed? | Yes, CapsoVision is a public company listed on NAS. |
| What is the stock symbol of CapsoVision? | CapsoVision trades under CV ticker. |
| When did CapsoVision go public? | CapsoVision went public in 2025. |
| Who are competitors of CapsoVision? | Similar companies to CapsoVision include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of CapsoVision? | CapsoVision's current market cap is $189M |
| Is CapsoVision profitable? | Yes, CapsoVision is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
